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Abstract: Studies of bacterial transcriptomics during bloodstream infections are limited 23 
to-date because unbiased extraction of bacterial mRNA from whole blood in sufficient 24 
quantity and quality has proved challenging. We addressed the key aspect of this issue 25 
and investigated approaches for the lysis of the human blood cells and the stabilisation 26 
of bacterial RNA in human whole blood samples containing E. coli cells. We compared 27 
four lysis agents: Triton X-100, saponin, ammonium chloride and the commercial MolYsis 28 
lysis buffer CM for their ability to yield high amounts of undegraded RNA and investigated 29 
their impact on the bacterial gene expression. For low cell numbers the best mRNA yields 30 
were obtained if the commercial RNAprotect reagent was added directly to the blood 31 
sample without prior lysis of the blood cells. Using this protocol, significant amounts of 32 
human RNA were co-purified but did not have a negative impact on qPCR detection of 33 
the bacterial mRNA. Importantly, at low concentrations of bacterial RNA, moderate 34 
amounts of co-purified human RNA had a positive effect on the yield of bacterial mRNA. 35 
Among the tested lysis agents Triton X-100 was the fastest in lysis and reduced the 36 
human mRNA background by three to four orders of magnitude compared to stabilisation 37 
without prior lysis. As anticipated, treatment with lysis agents was found to be associated 38 
with changes in bacterial gene expression. However, these changes were below 1.5-fold 39 
for the genes investigated. This study provides a framework for the choice of the most 40 
suitable sample preparation method to study bacterial bloodstream infections.  41 
  42 
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1. Introduction 43 
Bacterial bloodstream infections are a serious and increasing healthcare problem. (Artero 44 
et al., 2010; Lark et al., 2001; Martin et al., 2003) Therefore, there is growing interest in 45 
bacterial RNA extracted from human whole blood for diagnostic and research purposes. 46 
(Barczak et al., 2012; Graham et al., 2005; Macfarlane & Dahle, 1993) We focussed on 47 
E. coli because it is the most common pathogen found in bloodstream infections (Opota 48 
et al., 2015; Wilson et al., 2011) and due to its frequent use in sepsis research (Bhatty et 49 
al., 2012; Machuca et al., 2016; Skorup et al., 2014). The analysis of bacterial gene 50 
expression can elucidate the interactions between the pathogen and the host and 51 
improves our understanding of infection. Additionally, there is potential for molecular 52 
diagnostics as bacterial mRNA can reveal information about the etiologic pathogen as 53 
well as its antibiotic susceptibilities. (Barczak et al., 2012) Furthermore, bacterial rRNA 54 
can be used for pathogen detection and identification (Fujimori et al., 2010; Matsuda et 55 
al., 2007; Sakaguchi et al., 2010) and has an advantage over DNA due to its high copy 56 
number (Arfvidsson & Wahlund, 2003; Bremer & Dennis, 2008).  57 
We suspect that the wider use of bacterial RNA as a tool in the study and diagnostics of 58 
bloodstream infections has been hampered by the difficulty of extracting target bacterial 59 
RNA from whole blood specimen in sufficient quantity and of adequate purity for further 60 
analysis. Co-purification of PCR inhibitors such as haemoglobin (Akane et al., 1994), 61 
anticoagulants (Yokota et al., 1999), leucocyte DNA (Morata et al., 1998) or IgG (Al-Soud 62 
et al., 2000), the large excess of human blood cells (Song et al., 2014) and the presence 63 
of nucleases (Tan & Yiap, 2009) are amongst the recognised obstacles in the analysis of 64 
bacterial DNA from blood and we expected similar problems with the analysis of bacterial 65 
4 
 
RNA. Another challenge when investigating bacterial gene expression is the intrinsically 66 
short half-life of bacterial mRNAs (Bernstein et al., 2002; Hambraeus et al., 2003), which 67 
requires stabilisation immediately after the collection of the sample.  68 
Extraction of bacterial rRNA from whole blood has been demonstrated using microfluidic 69 
devices (Rogacs et al., 2012) as well as conventional methods (Matsuda et al., 2007). 70 
Analysis of bacterial gene expression in whole blood using a variety of other extraction 71 
methods has also been reported. In some studies, blood cells were lysed (e.g. with 72 
saponin) prior to RNA stabilisation (Hedman et al., 2012), whereas in others bacterial 73 
gene expression was stabilised first, followed by blood cell lysis with erythrocyte lysis 74 
buffer (Echenique-Rivera et al., 2011; Mereghetti et al., 2008; Del Tordello et al., 2012). 75 
In another approach, the use of dedicated blood cell lysis agents was avoided altogether 76 
and only a reagent for the stabilisation of the bacterial gene expression was applied. 77 
(Barczak et al., 2012; Orihuela et al., 2004)  78 
To our knowledge, a systematic analysis of the RNA yield and quality achieved with the 79 
different approaches has not been published to-date but would benefit future studies. In 80 
this work, we present the analysis of different methods of blood cell lysis and RNA 81 
stabilisation with respect to bacterial RNA yield, integrity and purity. Moreover, we discuss 82 
the influence of the lysis agents on the bacterial gene expression and the effect of co-83 
purified human RNA on the quantification of bacterial mRNA. We used four different lysis 84 
buffers: (1) ammonium chloride solution (often referred to as red blood cell lysis buffer) is 85 
commonly used to remove most of the cellular particles of a whole blood sample and thus 86 
facilitates the extraction of bacterial nucleic acids. (Shortman et al., 1972) However, it 87 
does not lyse white blood cells, leading to significant co-purification of human DNA and 88 
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RNA; (2) the commercial, chaotropic MolYsis buffer CM is used in a kit designed for the 89 
extraction of bacterial DNA from human whole blood (Hansen et al., 2009; Mccann & 90 
Jordan, 2014) and leads to the lysis of all human blood cells; (3) saponin is known to 91 
cause holes in the membranes of mammalian cells (Bangham & Horne, 1962), thus 92 
leading to specific lysis of these cells. It has been used for the lysis of blood cells to enable 93 
the direct detection of bacteria from blood cultures (Chen et al., 2013; Meex et al., 2012) 94 
or to lyse the blood cells for subsequent gene expression studies (Hedman et al., 2012); 95 
and finally (4) Triton X-100 which, in combination with a high pH buffer, has been 96 
described to be a very effective lysis agent for red and white blood cells, while pathogens 97 
remain intact. (BIOCARTIS S.A., 2012; Zelenin et al., 2015) 98 
For the stabilisation of the bacterial RNA and the suppression of the synthesis of new 99 
RNA molecules we used the commercially available RNAprotect Bacteria reagent. The 100 
main component of this agent is described as tetradecyltrimethylammonium bromide. 101 
(QIAGEN Ltd, 2015) We applied it either directly to the blood sample or after lysis of the 102 
human blood cells. We also investigated the suitability of the commercial PAXgene 103 
reagent for the stabilisation of bacterial gene expression in whole blood specimen without 104 
prior lysis of the blood cells. The reagent was originally designed for the stabilisation of 105 
human mRNA in whole blood. (Rainen et al., 2002) 106 
  107 
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2. Methods 108 
Culturing of E. coli cells 109 
E. coli CFT073 (Luo et al., 2009; Welch et al., 2002) was used throughout this study. 110 
When required, the strain was recovered from a glycerol stock onto LB agar (Fisher 111 
Scientific, Loughborough, UK) plates and incubated overnight at 37°C. Overnight liquid 112 
cultures were grown in 3 ml of IST broth (Oxoid, Basingstoke, UK) in a Multitron standard 113 
shaking incubator (Infors, Basel, Switzerland) (37°C; 200 rpm). The next day, 50 µl of the 114 
10-4 dilution (≈104 c.f.u.) were added to 3 ml of fresh IST broth in a 15 ml reaction tube. 115 
The culture was grown for 5 h to mid-exponential phase (37°C; 200 rpm). Bacterial cells 116 
from 500 µl of the culture (≈2x107 c.f.u.) were harvested by 3 min of centrifugation at 117 
5000x g in a 5415 D tabletop centrifuge (Eppendorf, Hamburg, Germany). The 118 
supernatant was discarded and the pellet was resuspended in 500 µl of human whole 119 
blood (anticoagulant: EDTA; Seralab, West Sussex, UK) or fresh IST broth. For 120 
experiments with low cell numbers 25 µl of a 10-2 dilution (≈104 c.f.u.) of the mid-121 
logarithmic culture were spiked directly into 500 µl of whole blood or fresh IST broth. 122 
Stabilisation of bacterial RNA 123 
Four lysis buffers for human whole blood, used for the removal of human cells in the 124 
process of bacterial DNA extraction, were tested for their suitability for bacterial RNA 125 
extraction. Volumes, concentrations and pH values were as suggested by the 126 
manufacturer or as used in the literature. Incubation times were kept the same for all lysis 127 
agents to ensure comparability. To lyse blood cells, the blood was mixed with either (1) 128 
500 µl of 1 % [v/v] Triton X-100 (Sigma-Aldrich, Gillingham, UK) in cold 500 mM 129 
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carbonate buffer, pH 10.0 (Sigma-Aldrich, Gillingham, UK), (2) 500 µl of 5 % [w/v] saponin 130 
(Sigma-Aldrich, Gillingham, UK) in cold PBS buffer (Fisher Scientific, Loughborough, UK), 131 
(3) 500 µl of 0.83 % [w/v] NH4Cl in cold 0.01 M Tris-HCl buffer, pH 7.5 (Sigma-Aldrich, 132 
Gillingham, UK) or (4) 125 µl of cold MolYsis buffer CM (Molzym, Bremen, Germany). 133 
The samples were incubated for a maximum of 30 s and centrifuged at 8000x g for 3 min 134 
to recover the bacterial cells. The supernatant was discarded and the bacterial pellet was 135 
resuspended in a mixture of 500 µl of IST broth and 1000 µl of RNAprotect Bacteria 136 
reagent (Qiagen, Hilden, Germany). If no dedicated lysis agent was applied, 1000 µl of 137 
RNAprotect reagent were added directly to the whole blood or the IST broth. Solutions 138 
were mixed by inversion, incubated for 15 min at room temperature, then centrifuged at 139 
6000x g for 6 min. The supernatant was discarded and the remaining pellet was frozen at 140 
-80°C until RNA extraction.  141 
Alternatively, blood with bacteria was first stabilised with RNAprotect before adding a lysis 142 
agent. After 15 min incubation at room temperature the solution was centrifuged for 6 min 143 
at 6000x g. The supernatant was discarded and the pellet was resuspended in a mix of 144 
500 µl of IST broth and one of the lysis buffers described above. The sample was then 145 
incubated at room temperature for 5 min on a roller mixer. After centrifugation at 6000x g 146 
for 6 min the supernatant was decanted and the pellets were frozen at -80°C until RNA 147 
extraction.  148 
For the stabilisation with the PAXgene reagent 500 µl of whole blood with bacteria were 149 
mixed with 1.38 ml of PAXgene reagent (PreAnalytiX, Hombrechtikon, Switzerland) and 150 
incubated overnight at room temperature. The next day, samples were centrifuged at 151 
5000x g for 10 min. The supernatant was discarded and pellets were washed with 800 µl 152 
of nuclease free water (Life Technologies, Carlsbad, CA, USA). Samples were 153 
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centrifuged again (5000x g for 10 min) and RNA extraction was performed immediately 154 
as described below.  155 
RNA extraction 156 
RNA was extracted using a modified protocol for the RNeasy Mini kit (Qiagen, Hilden, 157 
Germany). Pellets were resuspended in 200 µl of TE buffer (Life Technologies, Carlsbad, 158 
CA, USA) containing 15 mg/ml lysozyme (Sigma-Aldrich, Gillingham, UK) and 10 µl of 159 
proteinase K (Qiagen, Hilden, Germany). Depending on the extent of the lysis of the blood 160 
cells the resuspension could be tedious and require time due to the viscosity of the pellet.  161 
However, all pellets were resuspended completely. The solution was incubated on a roller 162 
mixer for 10 min at room temperature. To lyse the bacterial cells, 700 µl of buffer RLT (kit 163 
component) with 10 µl of β-mercaptoethanol (Sigma-Aldrich, Gillingham, UK) were 164 
added. After vigorous vortexing the samples were incubated for a further 20 min on the 165 
roller mixer. Then, 500 µl of absolute ethanol (VWR, Lutterworth, UK) were added and 166 
the solution was mixed vigorously using a vortex mixer. The lysate (≈1.4 ml) was loaded 167 
onto an RNeasy spin column in two 700 µl batches by centrifugation at 8000x g for 1 min. 168 
The column was washed two times with 350 µl of buffer RW1 (kit component) and two 169 
times with 500 µl of buffer RPE (kit component), then transferred into a fresh collection 170 
tube and centrifuged at 8000x g for 5 min to remove residual ethanol. Finally, the column 171 
was transferred to a new 1.5 ml reaction tube. For elution, 45 µl of nuclease free water 172 
were added and the column was centrifuged at 8000x g for 1 min. The flow through was 173 
added to the column again and the centrifugation was repeated. The eluate was placed 174 
on ice immediately. The amount of extracted nucleic acid was assessed by measurement 175 
of the absorption at 260 nm using a NanoDrop ND-1000 spectrophotometer (Thermo 176 
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Fisher Scientific, Wilmington, DE, USA). The purity of the sample was assessed by 177 
measurement of the absorption at 230 and 280 nm.  178 
DNA removal 179 
DNA was removed with the TURBO DNA-free kit (Life Technologies, Carlsbad, CA, USA) 180 
according to the manufacturer’s instructions. The concentration and purity of the 181 
remaining RNA was again assessed with the NanoDrop ND-1000 spectrophotometer.  182 
Measurement of the RNA integrity 183 
RNA integrity was measured by capillary electrophoresis using a 2100 Bioanalyzer 184 
instrument (Agilent Technologies, Santa Clara, CA, USA) with the RNA 6000 Nano kit 185 
(Agilent Technologies, Santa Clara, CA, USA) following the manufacturer’s instructions. 186 
Real-time PCR 187 
From 12 µl of undiluted RNA in a 20 µl reaction cDNA was synthesised using the Tetro 188 
cDNA synthesis kit (Bioline, London, United Kingdom) according to the manufacturer’s 189 
instructions. The final cDNA was diluted if higher volumes were required to allow for the 190 
analysis of multiple genes. A master mix was prepared from the SensiFAST SYBR Lo-191 
ROX reagent (Bioline, London, United Kingdom), nuclease free water and the 192 
corresponding primers (Metabion, Planegg, Germany) (final concentration: 0.4 µM). The 193 
primer sequences are depicted in Table 1.  194 
16 µl of mastermix were mixed with 4 µl of cDNA template for a total volume of 20 µl per 195 
reaction. PCRs were performed on a Mx3000P instrument (Stratagene-Agilent 196 
Technologies, La Jolla, CA, USA) using the following conditions: 2 min initial denaturation 197 
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at 95°C, followed by 40 cycles of 5 s at 95°C, 10 s at 60°C and 20 s at 72°C. The efficiency 198 
and specificity of all primers targeting bacterial sequences were assessed beforehand 199 
and only primer pairs with efficiencies higher than 1.95 were used. Absence of sample 200 
contamination by undigested genomic DNA was verified by RNA controls that did not 201 
undergo cDNA synthesis (“no RT controls”). Negative controls (blood or IST broth without 202 
spiked-in bacteria) were used similarly to ensure the absence of bacterial contamination 203 
or unintended primer binding to cDNA synthesised from human RNA. 204 
Influence of Triton X-100 and saponin on the bacterial gene expression 205 
E. coli CFT073 cells were grown in IST broth to the mid-logarithmic phase. 500 µl of the 206 
culture containing ≈2x107 c.f.u. were treated with 1 ml of RNAprotect for 15 min 207 
immediately. Another 500 µl of the same culture were treated with either 500 µl of 1 % 208 
[v/v] Triton X-100 in 500 mM cold carbonate buffer (pH 10.0) or 500 µl of 5 % [w/v] 209 
saponin in cold PBS buffer for 30 s. After centrifugation (5000x g for 3 min) a mix of 500 µl 210 
of IST broth and 1 ml of RNAprotect was added. RNA was extracted as described above 211 
and cDNA was synthesised from 600 ng of RNA. Real-time PCR analysis was performed 212 
for two reference genes (gapA, adk) and four genes (rpoS, rpoH, pspA, cpxP) that are 213 
known to respond to various stress conditions, such as a high pH, at a transcriptional 214 
level (Chung et al., 2006; Danese & Silhavy, 1998; Darwin, 2005; Maurer et al., 2005; 215 
Weiner et al., 1991). Gene expression analysis was done using the Livak method (Livak 216 
& Schmittgen, 2001) and gapA for normalisation. Briefly, the difference (∆Cq) in the Cq 217 
values between gapA and the gene of interest was calculated in the control (no lysis 218 
agent) and under the condition of interest (treatment with Triton X-100 or saponin). 219 
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Subsequently, the difference of both ∆Cq values was obtained, referred to as ∆∆Cq. Error 220 
bars represent the standard deviation of the ∆Cq values for each condition. 221 
Impact of spiked-in human RNA on real-time PCR detection of bacterial RNA 222 
All steps were carried out in a UV PCR cabinet to avoid contamination. Bacterial RNA 223 
was extracted from IST grown cultures, human RNA was extracted from whole blood 224 
(without bacteria) after mixing with RNAprotect. The initial concentrations of human and 225 
bacterial RNA were determined with the Nanodrop ND-1000 instrument. Appropriate 226 
amounts were obtained by serial dilution in nuclease free water. The combined species 227 
were used for cDNA synthesis and qPCR as described above. 228 
Statistical analysis 229 
Statistical differences were identified using one-way ANOVA with post-hoc Holm-Sidak 230 
tests. Differences were statistically significant at p<0.05 (*), p<0.01 (**), p<0.001 (***). 231 
The degree of spread of the data is shown as standard deviation.   232 
  233 
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3. Results 234 
RNA yield and integrity 235 
In a first step, we compared the total RNA yields after RNA extraction and DNA digest. 236 
DNA accounted for about 30 % of the initially extracted nucleic acid. Blood with and 237 
without bacteria was either treated with RNAprotect immediately or lysed prior to the 238 
stabilisation.  239 
The direct mixing of spiked blood and RNAprotect reagent without prior lysis of the human 240 
blood cells yielded about 40 - 50 % of the total bacterial RNA obtained from laboratory 241 
medium despite significant co-purification with human RNA (Fig. 1 (a)).  242 
This method also led to a clotting of the blood sample. The resuspension of the pellet was 243 
tedious, time consuming and required some practice (i.e. potentially leading to user 244 
dependent variability). Additionally, remainders of the blood caused strong contamination 245 
of the silica columns used for nucleic acid purification. Lysis of the human blood cells prior 246 
to the stabilisation of the bacterial gene expression resulted in a decrease of co-purified 247 
human total RNA (Fig. 1 (a), grey bars). The effect was rather small for saponin, NH4Cl 248 
and MolYsis buffer CM, while treatment with Triton X-100 resulted in a strong reduction 249 
of the background below the limit of detection of the NanoDrop spectrophotometer. Upon 250 
mixing with the whole blood Triton X-100 degraded the blood cells within seconds and 251 
yielded about 60 % of the bacterial RNA compared to an extraction from IST broth. 252 
Similarly, saponin caused fast degradation of the human blood cells with only a small 253 
debris pellet remaining. However, a significant co-purification of human total RNA was 254 
still observed and the recovery rate for bacterial total RNA was 40 %. The A260/230 and 255 
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A260/280 ratios of the extracted RNA samples were around 2 for all tested conditions, 256 
indicating the absence of high amounts of proteins or other contaminants (SI Fig. 1). If 257 
the blood was first incubated with RNAprotect, then treated with one of the lysis agents, 258 
no improvement of the RNA yield was observed. To the contrary, the RNA quality was 259 
lower and the Cq values of bacterial mRNAs higher (data not shown).  260 
To further investigate the reduction of the human RNA background after human blood cell 261 
lysis we measured the remaining amount of human β-actin mRNA by means of qPCR 262 
(Fig. 1 (b)). Samples directly stabilised with RNAprotect without prior treatment with a lysis 263 
agent displayed the highest amount of β-actin mRNA. Treatment with Triton X-100 264 
caused an increase of the Cq value by ≈12 units, corresponding to a 3 to 4 orders of 265 
magnitude decrease in the concentration of β-actin mRNA. Interestingly, the amount of 266 
detectable mRNA was reduced to a similar degree after lysis of the blood cells with 267 
saponin, despite large amounts of co-purified total RNA (Fig. 1 (a)). Compared to RNA 268 
stabilisation without prior application of a lysis agent, the amount of β-actin mRNA was 269 
slightly but not significantly lower when the blood cells were lysed with NH4Cl or MolYsis 270 
buffer CM (p value 0.84 and 0.68, respectively).  271 
The quality of the extracted RNA was assessed using capillary electrophoresis. The 272 
electropherograms are shown in Fig. 2 and an overview of the resulting RINs (RNA 273 
integrity numbers) is given in Fig. 1 (c). The electropherograms show two distinct peaks 274 
for the bacterial 16S and 23S rRNA in all samples. Significant amounts of human 18S 275 
rRNA and 28S rRNA were found in those samples that were stabilised immediately with 276 
RNAprotect and those treated with NH4Cl and MolYsis buffer CM (SI Fig. 2). No peaks 277 
for human RNA were detected when the blood was lysed with saponin, although large 278 
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amounts of human total RNA were measured by the NanoDrop (Fig. 1 (a)). The observed 279 
RINs indicate high quality RNA (RIN ≥ 8 (Imbeaud, 2005)) after blood cell lysis with Triton 280 
X-100 or saponin.  281 
Finally, the implications of the used sample preparation method on specific mRNA 282 
quantities determined by real-time PCR were investigated by comparing the mRNA 283 
derived Cq values for three bacterial reference genes (gapA, adk, gyrB) (Fig. 1 (d)). The 284 
best Cq values, similar to those of the IST reference, were obtained when the blood was 285 
lysed with saponin. RNAprotect added directly to the sample or after lysis of the blood 286 
cells with Triton X-100 yielded Cq values about ≈1.5 units higher than the IST standard. 287 
However, standard deviations and the ∆Cq values between the genes remained similar 288 
compared to the reference. Only after blood cell lysis with NH4Cl or MolYsis buffer CM 289 
we found a higher variability in the Cq value for gapA. 290 
When bacterial RNA was stabilised with the PAXgene reagent total RNA yields were 291 
slightly lower than with RNAprotect and the Cq values for the investigated bacterial genes 292 
were notably higher (SI Table 1). Therefore, RNAprotect was used for the stabilisation of 293 
bacterial RNA throughout the rest of this study. 294 
Influence of Triton X-100 and saponin on the bacterial gene expression 295 
Since Triton X-100 and saponin were found to be the most powerful lysis agents for the 296 
human blood cells we investigated their effects on the bacterial gene expression by 297 
comparing Cq values for selected genes from treated and untreated samples extracted 298 
from IST broth. 299 
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When treated with Triton X-100 the Cq values for all investigated genes were significantly 300 
higher than for the untreated control despite equal input of total RNA (Fig. 3 (a)).  301 
Total RNA yields and RINs were similar for treated and untreated samples, indicating that 302 
Triton X-100 did not affect the extraction process (SI Fig. 3). The average increase in the 303 
Cq values was dependent on the gene and varied between 0.56 (cpxP) and 1.33 (pspA). 304 
We hypothesised that the exposure to Triton X-100 leads to cell death. If the synthesis of 305 
new mRNA molecules is interrupted, their concentration is decreasing with a gene-306 
specific half-life. To investigate the viability of the E. coli cells a viable cell count before 307 
and after incubation with Triton X-100 was performed. The recovery rate of viable bacteria 308 
after exposure to Triton X-100 for 3.5 min (time necessary for blood cell lysis and 309 
subsequent centrifugation) was ≈0.001 %. After incubation with saponin the recovery rate 310 
of viable bacteria was ≈100 %. In this case, Cq values were similar to the untreated control 311 
except for rpoS and cpxP (Fig. 3 (c)).   312 
The treatment with either Triton X-100 or saponin was found to cause small but significant 313 
changes in the apparent observed expression of the investigated stress response genes 314 
(Fig. 3 (b), (d)). A 0.52-fold upregulation in the cpxP levels was observed for Triton X-100 315 
and a 0.42-fold downregulation for saponin. Furthermore, a 0.26-fold downregulation of 316 
rpoS and a 0.58-fold upregulation of rpoH were observed after treatment with Triton X-317 
100 and saponin, respectively.   318 
Impact of spiked-in and co-purified human RNA on real-time PCR detection 319 
In the next step, we investigated whether the direct application of RNAprotect to the blood 320 
sample without prior lysis of the blood cells was associated with the co-purification of PCR 321 
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inhibitors. As leucocyte DNA is a known inhibitor of PCR detection of bacterial DNA we 322 
hypothesised that leucocyte RNA could have a similar effect on bacterial RNA as both 323 
are transformed into cDNA before quantification. 0.05 ng of total bacterial RNA extracted 324 
from IST-grown cultures were spiked with serial dilutions of human RNA extracted from 325 
human whole blood without bacteria. Assuming the extraction efficiency from Fig. 1 (a) 326 
(≈6 µg RNA from 2x107 cells) this amount of bacterial RNA corresponds to ≈2x102 c.f.u. 327 
For each mix cDNA synthesis was performed and the Cq values of a bacterial (gapA) and 328 
a human (β-actin) reference gene were investigated. The results are shown in Table 2.  329 
With the addition of human RNA a decrease in the Cq value of gapA was observed which 330 
was significant for human RNA quantities between 4 and 400 ng. The lowest Cq values 331 
were obtained when the bacterial RNA sample was spiked with 40 ng of human RNA 332 
(corresponding to a human RNA concentration of 2 ng/µl in the final cDNA synthesis 333 
reaction). The average decrease of the Cq value at this concentration was 2.69, 334 
corresponding to an apparent increase in the concentration of ≈6.5-fold. No further 335 
improvement was observed at higher concentrations of human RNA. To the contrary, the 336 
Cq value for gapA increased when 400 ng of human total RNA were added. However, the 337 
signal was still significantly better compared to the unspiked control. 338 
To investigate the impact of co-purified human RNA throughout the whole sample 339 
preparation and extraction process a much smaller amount (≈104 c.f.u.) of E. coli cells 340 
than in the previous experiments (≈2x107 c.f.u.) was spiked into 0.5 ml of whole blood to 341 
drastically decrease the ratio between bacterial and human RNA. The RNA was either 342 
stabilised with RNAprotect immediately or after lysis of the blood cells with Triton X-100 343 
or saponin. Again, a sample extracted from IST broth served as a reference. As a 344 
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measure for the amount of bacterial mRNA the Cq values for gapA, adk and gyrB were 345 
determined (Fig. 4).  346 
The best signals were obtained if the bacterial RNA was extracted from whole blood after 347 
direct stabilisation with RNAprotect or after lysis of the blood cells with saponin, while the 348 
extraction after blood cell lysis with Triton X-100 showed a lower efficacy, similar to the 349 
IST reference. These results confirmed the findings of the spiking experiment (Table 2) 350 
and demonstrate the beneficial impact of human RNA on the detection of small amounts 351 
of bacterial RNA.  352 
  353 
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4. Discussion 354 
RNA yield and integrity 355 
The yields of bacterial total RNA and mRNA as well as the RNA integrities after RNA 356 
extraction from human whole blood were compared to a reference extraction from 357 
laboratory medium. The obtained RNA yields matched the numbers described in the 358 
literature. Bremer et al. (2008) determined a total RNA content of 214 µg/109 cells 359 
(corresponding to 4.28 µg/2x107 cells) for E. coli growing with a doubling time of 24 min. 360 
(Bremer & Dennis, 2008) Our reference yields from IST broth were slightly higher 361 
(≈6 µg/2x107 cells) but cells grew with a lower doubling time (19 min) and RNA yields will 362 
differ between strains. In whole blood, satisfactory results with respect to the total and 363 
mRNA yield were obtained when RNAprotect was added directly to the blood sample 364 
although large amounts of human RNA were co-purified. The method avoids the 365 
treatment with a lysis agent which might alter the gene expression, e.g. by activation of 366 
the bacterial stress response. However, the observed contamination of the silica column 367 
with debris might lead to clogging and reduction of the binding capacity when using larger 368 
volumes of blood. Huge amounts of co-purified human RNA can also interfere with some 369 
downstream applications such as gene expression measurements with microarrays (Di 370 
Cello et al., 2005; La et al., 2008) or RNA sequencing (Rienksma et al., 2015). Triton X-371 
100 was the most effective lysis agent and significantly reduced the amount of co-purified 372 
human total RNA and mRNA. After lysis of the human blood cells with saponin the amount 373 
of detectable human mRNA was considerably reduced, although there was still a 374 
significant remainder of human total RNA. An explanation for this observation might be 375 
the high degree of human RNA degradation indicated by the absence of distinct rRNA 376 
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peaks in the electropherogram (SI Fig. 2) as degraded RNA yields significantly higher Cq 377 
values (Fleige et al., 2006). The main reason for the rather low efficacy of NH4Cl and the 378 
MolYsis lysis buffer might be the low temperature and the short exposure time (max. 30 s 379 
before centrifugation) used in our setup to keep the impact on the bacterial gene 380 
expression to a minimum. For the extraction of bacterial DNA from human whole blood 381 
the manual for the MolYsis Basic5 kit recommends 5 min incubation with the lysis buffer 382 
at room temperature. (Molzym, 2014) For NH4Cl other groups have used incubation times 383 
between 20 and 40 min (Brunck et al., 2014) and found a low efficacy of the red blood 384 
cell lysis after short incubation (Boyd et al., 2015).  385 
The RNA quality is crucial for downstream applications because of its impact on the 386 
results obtained from gene expression measurements using real-time PCR (Fleige et al., 387 
2006; Schroeder et al., 2006), microarrays (Thompson et al., 2007) or RNA 388 
sequencing (Gallego Romero et al., 2014). In this study, the RNA integrity number was 389 
satisfactory after lysis of the blood cells with either Triton X-100 or saponin, followed by 390 
stabilisation with RNAprotect. The RIN was lower for direct stabilisation with RNAprotect 391 
or after lysis blood cell lysis with NH4Cl and MolYsis buffer CM. However, these were the 392 
conditions with the highest amounts of co-purified human RNA which forms a background 393 
(Fig. 1 (a), SI Fig. 1) and might interfere with the RIN calculation.  394 
Influence of Triton X-100 and saponin on the bacterial gene expression 395 
We found an effect of both, Triton X-100 and saponin, on the bacterial gene expression. 396 
Saponin kept the cells alive and activated stress response genes (Fig. 3 (d)). Triton X-397 
100 triggered cell death within the time frame of sample preparation. After cell death 398 
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mRNA molecules begin to degrade with a gene specific half-life of typically three to eight 399 
minutes (Bernstein et al., 2002) until an RNA stabilising agent is added. Lysis with Triton 400 
X-100 will introduce a bias as mRNA species degrade with different half-lifes. Additionally, 401 
a stress response might be induced before cell death. Especially, the observed 402 
upregulation of cpxP could be a response to the alkaline pH of the Triton X-100 solution. 403 
(Danese & Silhavy, 1998) However, for the genes investigated here the introduced bias 404 
was found to be small for both lysis agents. Consequently, all samples should be treated 405 
in the same way, i.e. extracted from whole blood using the same lysis agent and 406 
incubation times to minimise the impact of the sample preparation bias.  407 
Impact of spiked-in and co-purified human RNA on real-time PCR detection 408 
Initial experiments conducted here used bacterial concentrations of 107 c.f.u./ml, which is 409 
a  common amount for gene expression studies in laboratory setups (Barczak et al., 2012; 410 
Hedman et al., 2012; Del Tordello et al., 2012). However, in clinical bloodstream infections 411 
the bacterial concentrations often range between 100 and 103 c.f.u./ml (Dietzman et al., 412 
1974; Henry et al., 1983; Werner et al., 1967) drastically decreasing the ratio between 413 
bacterial and human RNA. As such low concentrations are relevant for diagnostic 414 
applications we conducted additional experiments with 104 c.f.u. (Fig. 4) and bacterial 415 
RNA corresponding to 102 c.f.u. (Table 2). It is important to note that the concentration of 416 
cells used in these experiments were defined by the concentration of mRNA per cell (10-417 
3 – 100 copies/cell in E. coli (Taniguchi et al., 2010)). To enhance the feasibility of 418 
transcription measurements for clinical application technical advancements for mRNA 419 
detection will be required. We found that moderate amounts of co-purified human RNA 420 
had a stabilising effect on small amounts of bacterial RNA. This seems contradictory to 421 
21 
 
observations made by other groups where a reduction of the human DNA background 422 
increased the sensitivity of bacterial DNA detection by means of qPCR (Loonen et al., 423 
2013; Zhou & Pollard, 2012), probably by reduction of mispriming and more efficient 424 
amplification (Song et al., 2014). The stabilising effect of the human RNA observed here 425 
might be due to a relative reduction of adsorption of bacterial RNA to lab plastics as well 426 
as a relative protection of the target molecules from trace amounts of RNAses which 427 
outweigh any potential negative effects. Thus, the co-purified human RNA acts as a 428 
carrier RNA. Similar protective effects of large amounts of foreign RNA have been 429 
described by other groups. (Andreasen et al., 2010; Sanders et al., 2011) Consequently, 430 
the direct addition of RNAprotect without prior lysis of the blood cells gave the best results 431 
for low numbers of bacterial cells with respect to signal intensity. Similar observations 432 
were made after lysis of the human blood cells with saponin. This protocol yielded highly 433 
degraded human RNA and facilitated the extraction process considerably by removal of 434 
cellular debris. 435 
Conclusion 436 
We successfully demonstrated the extraction of bacterial RNA from human whole blood 437 
and discussed the implications of the lysis of the human blood cells. A key conclusion of 438 
this study is that the selection of the most appropriate sample preparation method 439 
depends on factors such as number of bacteria, the impact of human RNA on downstream 440 
measurements or, potentially, sample volume. If gene expression experiments are 441 
performed with large numbers of bacteria grown in whole blood, the direct RNA 442 
stabilisation with RNAprotect is a good choice since the volume of blood is probably 443 
relatively small and a lysis agent that has a potential effect on the bacterial gene 444 
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expression is not required. However, it is not entirely clear whether RNAprotect works as 445 
effectively in blood as in laboratory medium. Furthermore, large amounts of human RNA 446 
are co-purified which may not be desirable for certain subsequent applications such as 447 
RNA sequencing or microarray experiments. If the experiment involves large amounts of 448 
human whole blood, lysis of the human blood cells with Triton X-100 or saponin may be 449 
useful as this facilitates the extraction considerably. Under these conditions the human 450 
RNA background is reduced significantly thus limiting the bias on downstream 451 
applications. This work will facilitate future fundamental studies to understand bacterial 452 
gene expression during blood stream infections as well as diagnostics developments. 453 
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Table 1: Primers used for quantification of bacterial and human cDNA. 689 
Species Gene description Abbr. Forward primer Reverse primer 
E. coli 
CFT073 
glyceraldehyde-3-phosphate 
dehydrogenase 
gapA 
AGTTGACCTGAC
CGTTCGTC 
ACCCGCTTTAGCA
TCGAACA 
E. coli 
CFT073 
adenylate kinase adk 
CTCCGAGCTGGG
TAAACAAG 
AGTTCGTCGGTGA
CCAGTTT 
E. coli 
CFT073 
DNA gyrase subunit B gyrB 
GGCGTTTCCATTC
GTCTG 
CCGCCTTCATAGT
GGAAGTG 
E. coli 
CFT073 
RNA polymerase factor sigma S rpoS 
ACGGGTAGGAGC
CACCTTAT 
TCCTCTTCGGCCA
AATCGTT 
E. coli 
CFT073 
RNA polymerase factor sigma-32 rpoH 
CCACCAAAGCGC
AACGTAAA 
AATCGTCGTCGGA
AGACAGG 
E. coli 
CFT073 
phage shock protein PspA pspA 
TTTGCCGACATCG
TGAATGC 
ACGCACCAGTTTC
TGTGGAT 
E. coli 
CFT073 
periplasmic repressor CpxP cpxP 
TGATGCGCATAGT
TACCGCT 
TCAGCAGCGTGGC
TTAATGA 
Homo 
sapiens 
Β-actin - 
TCACCCACACTGT
GCCCATCTACGA 
(Barber et al., 2005) 
CAGCGGAACCGCT
CATTGCCAATGG 
(Barber et al., 2005) 
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Table 2: Cq values for gapA (bacterial) and β-actin (human) after spiking of 0.05 ng of bacterial RNA 692 
with different amounts of human RNA extracted from whole blood. Cq values for gapA were compared 693 
to the unspiked control. n=3. 694 
Spiked in human 
RNA [ng] 
Cq gapA (± SDV) p value  Cq β-actin (± SDV) 
0 32.47 (± 0.81) - - 
0.04 32.25 (± 0.51) 0.7137 34.73 (± 0.33) 
0.4 32.04 (± 0.53) 0.4865 32.03 (± 0.85) 
4 30.66 (± 0.55) 0.0326 26.95 (± 1.33) 
40 29.78 (± 0.74) 0.0131 22.60 (± 0.85) 
400 30.37 (± 0.86) 0.0364 19.55 (± 1.12) 
neg. control*  - - 19.39 (± 2.05) 
* 400 ng of human RNA, 0 ng of bacterial RNA 695 
 696 
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 697 
Fig. 1: Extraction of bacterial RNA from whole blood. (a) RNA yields after mixing whole blood with 698 
RNAprotect immediately (“no lysis agent”) or after prior lysis of the blood cells with Triton X-100, saponin, 699 
NH4Cl or MolYsis buffer CM. To obtain reference values extraction was also performed from IST broth after 700 
stabilisation with RNAprotect. Grey bars represent the RNA yield from 0.5 ml of human whole blood or IST 701 
broth alone, black bars represent the yield after spiking of 0.5 ml human whole blood or IST broth with 702 
≈2x107 E. coli CFT073 bacteria. n = 6. (b) Cq values for human β-actin mRNA after treatment of 0.5 ml of 703 
whole blood or IST broth with RNAprotect directly, or after prior lysis of the blood cells. † indicates no Cq 704 
value (absence of β-actin mRNA). n = 3. (c) RNA integrity numbers (RINs) after stabilisation of the bacterial 705 
gene expression with RNAprotect immediately or after prior lysis of the blood cells. n = 6. (d) Cq values for 706 
gapA, adk and gyrB after stabilisation of the bacterial gene expression with RNAprotect immediately or after 707 
prior lysis of the blood cells. n = 6.  708 
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 709 
Fig. 2: Electropherograms of RNA obtained from whole blood samples containing E. coli CFT073 710 
bacteria. RNA was extracted after adding RNAprotect to the sample immediately or after prior lysis of the 711 
human blood cells with Triton X-100, saponin, NH4Cl or MolYsis buffer CM. The last electropherogram 712 
represents RNA extracted from IST broth after stabilisation with RNAprotect. 16S and 23S rRNA peaks 713 
represent bacterial rRNA, 18S and 28S rRNA peaks represent human rRNA.  714 
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 715 
Fig. 3: Impact of lysis agents for human whole blood on the bacterial gene expression. (a), (c) 716 
Comparison of the Cq values of two reference genes (gapA, adk) and four genes of the bacterial stress 717 
response (rpoS, rpoH, pspA, cpxP) between cells treated with Triton X-100 (a) or saponin (c) and untreated 718 
controls. (b), (d) Observed fold changes after treatment with Triton X-100 (b) or saponin (d) after 719 
normalisation to gapA. n = 5. 720 
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 721 
Fig. 4: Impact of co-purified human RNA on the detection of small amounts of bacterial RNA. mRNA 722 
abundance (Cq values) for gapA, adk and gyrB was measured after RNA extraction from 104 E. coli cells 723 
spiked into 0.5 ml of whole blood or IST broth. The RNA was extracted from IST broth after stabilisation of 724 
the gene expression with RNAprotect (standard), or from whole blood after direct stabilisation with 725 
RNAprotect or prior lysis of the blood cells with Triton X-100 or saponin. n = 3. No Cq values were obtained 726 
for the negative control (human whole blood without spiked-in bacteria). 727 
 728 
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Supplementary information 1 
SI Table 1: Extraction of bacterial RNA from human whole blood after stabilisation with PAXgene 2 
reagent. n = 6. 3 
Parameter Value (± SDV) 
Total RNA yield (0.5 ml of whole blood spiked 
with 2x107 c.f.u. of E. coli CFT073 bacteria) [ng] 
2.47 (± 0.66) 
Total RNA yield (0.5 ml of whole blood without 
spiked-in bacteria) [ng] 
0.78 (± 0.12) 
A260/280 ratio (0.5 ml of whole blood spiked with 
2x107 c.f.u. of E. coli CFT073 bacteria) 
1.98 (± 0.03) 
A260/230 ratio (0.5 ml of whole blood spiked with 
2x107 c.f.u. of E. coli CFT073 bacteria) 
1.97 (± 0.07) 
Cq value for human β-actin mRNA after RNA 
extraction from 0.5 ml of whole blood 
20.17 (± 1.56) 
RIN  8.1 (± 0.36) 
Cq values for bacterial reference genes after RNA 
extraction from 0.5 ml of whole blood spiked with 
2x107 c.f.u. of E. coli CFT073 bacteria 
gapA: 19.43 (± 0.85) 
adk: 21.08 (± 0.41) 
gyrB: 21.02 (± 0.31) 
2 
 
 4 
SI Fig. 1: A260/280 and A260/230 ratios of RNA extracted from human whole blood with spiked-in 5 
E. coli CFT073 bacteria. Extraction was either performed after mixing of whole blood with RNAprotect 6 
immediately (“no lysis agent”) or after prior lysis of the blood cells with Triton X-100, saponin, NH4Cl or 7 
MolYsis buffer CM. n = 6. 8 
3 
 
 9 
SI Fig. 2: Electropherograms of RNA obtained from whole blood samples without E. coli CFT073 10 
bacteria. RNA was extracted after adding RNAprotect to the sample immediately or after prior lysis of the 11 
human blood cells with Triton X-100, saponin, NH4Cl or MolYsis. The last electropherogram represents 12 
RNA extracted from IST broth after stabilisation with RNAprotect. 13 
 14 
SI Fig. 3: Extraction of bacterial RNA from IST broth after treatment with Triton X-100. Yields are 15 
shown in (a) and RNA integrity numbers are shown in (b). 16 
